Just a few thoughts. We have no breakdown on the status of customization activities and milestones timelines from many of the existing supply contracts or any of the other 20 active programs. There is also the new device that AS mention of the Jefferies session that has not been discloses/revealed as of today.
Since Sept 2013, only one timeline has clearly been revealed and that was Sanofi which stated 150 after a four year ramp up. Hikma was a rapid ramp up but the specifics of clarity with regards to volume of devices timeline was not revealed.
So with regards to meeting the requirements of Orbimed, I think it's premature to throw in the towel with so many unknowns.
The SP movement of this equity is "news driven" and then retraces accordingly waiting for the date that the revenue kicks in for sustainable growth. Yes large upfront payments are welcome and impressive, like our growing list of top Pharma's, but the catalyst will be announcements of revenue from device sales. +++
It's coming like the undisclosed list of existing customers program add ons. And, the activities of the unknown customer programs!!!
A few more thoughts, focus on the large segments!! Check++++
OrbiMed has a very long history of funding successful companies. Check++++
Don't underestimate the value of the Sanofi relationship. Check++++
We wait. JMHO RRM
UNS Price at posting:
48.0¢ Sentiment: Hold Disclosure: Held
